Zimmer Biomet Holdings Inc

Zimmer Biomet has extended its exclusive distribution and supply agreement with THINK Surgical for their wireless, handheld TMINI Miniature Robotic System. This system is designed for use with Zimmer Biomet's Persona Knee System to improve surgical precision in knee arthroplasty. The extension aims to increase the adoption of the TMINI system among orthopedic surgeons in the US and reflects the success of their partnership.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) and Think Surgical, Inc. have extended their Limited Exclusive Distribution and Supply Agreement. This multi-year extension allows Zimmer Biomet to continue distributing an exclusive version of Think Surgical's wireless, handheld TMINI Miniature Robotic System, which is compatible with Zimmer Biomet's Persona Knee System for total knee arthroplasty. Both companies highlighted the system's value in meeting customer needs for a wireless, handheld robotic system and plan to expand access for surgeons and patients across the US.

Zimmer Biomet Holdings, Inc. and THINK Surgical, Inc. have announced a multi-year extension of their exclusive distribution and supply agreement. This partnership focuses on Zimmer Biomet distributing THINK Surgical's wireless, handheld TMINI Miniature Robotic System, which is compatible with Zimmer Biomet's Persona Knee System. Both companies anticipate that the extension will accelerate the adoption of the TMINI System, expanding access for surgeons and patients across the U.S.

Zimmer Biomet Holdings Inc. reported strong Q2 FY2026 results, exceeding expectations with 4.8% reported growth and 4% organic constant currency growth. The company raised its full-year revenue and EPS guidance, citing momentum from its U.S. sales force transformation, new product launches like the iodine-coated hip platform in Japan and ROSA Shoulder, and healthy market dynamics. Strategic priorities include people and culture, operational excellence, and innovation and diversification, with a focus on high-growth segments and potential M&A aligned with these goals.

Zimmer Biomet (ZBH) saw a 3.4% stock increase, likely driven by improved sentiment regarding its growth outlook. Investors are considering the company's raised 2026 guidance and a recent analyst note highlighting revenue potential from its iodine-coated hip implant launch in Japan. The company is set to report its Q3 2026 results on November 4th.

The Morningstar Healthcare Index significantly outperformed the Morningstar US Index in the past year, driven by defensive investments and breakthroughs in cancer therapies. Despite near-term challenges for healthcare plans, innovation is expected to support the biopharma sector. Morningstar highlights GE Healthcare, BioMarin Pharmaceutical, and Medline as top undervalued picks within the sector.

Zimmer Biomet Holdings Inc. (ZBH) saw its stock rise by 3.40% to $92.17, outperforming a mixed market day where the Dow Jones Industrial Average gained and the S&P 500 Index declined. This marks the third consecutive day of gains for the company's stock. The positive movement occurred despite the broader market's mixed performance.

Stryker has invested $400 million in CMR Surgical, becoming the exclusive US sales agent for CMR's Versius robotic surgery platform and securing an option to acquire the company in the future. This strategic move allows Stryker to enter the high-growth soft-tissue robotics market, complementing its existing strengths in orthopaedic robotics. The alliance is expected to expand the adoption of robotic-assisted surgery in hospitals and ambulatory surgery centers across a broad range of procedures.

This article reports on a Form 4 filing for Zimmer Biomet Holdings Inc., dated October 12. Form 4s are SEC filings that disclose changes in beneficial ownership of a company's stock by its insiders. The article includes the stock symbol ZBH and its performance (+3.40%).

Zimmer Biomet (ZBH) is presented as a strong value stock candidate based on the Zacks Rank system. The article highlights ZBH's favorable valuation metrics, including its P/E, P/B, and P/CF ratios, which are all lower than its industry averages. With a Zacks Rank #2 (Buy) and a Value grade of A, ZBH appears to be undervalued with a strong earnings outlook.